Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
27 July 2020

ORYZON presents vafidemstat clinical data from its Phase IIa clinical trial ETHERAL in Alzheimer’s at the virtual AAIC-2020 conference

22 July 2020

ORYZON First Half Ended June 30, 2020 Results and Corporate Update

6 July 2020

ORYZON presents final data from its Phase IIa clinical trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020

28 July 2020

Epigenetic Therapeutic Targets Summit 2020

27-31 July 2020

Alzheimer's Association International Conference, AAIC 2020

4-7 July 2020

28th European Congress of Psychiatry, EPA 2020

2 July 2020

ORYZON to present at upcoming virtual international conferences

25 June 2020

ORYZON raises its share capital

19 June 2020

ORYZON enters into pioneering precision medicine collaboration with La Paz Hospital in Madrid for Phelan-McDermid Syndrome

15 June 2020

ORYZON initiates a new project to explore the efficacy of vafidemstat in the treatment of schizophrenia

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Current page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel